Michael Sloan is Vice President of Business Development at Almac Diagnostics Limited. Sloan has a BSC in commerce and MSC in corporate Leadership. Educated in the University of Birmingham, Napier University and the Ivey Business School, Canada. He has over 20 years experience in managing sales and marketing teams in the biotech and medical device sect and has worked in both start up and multinational companies.
Sloan formerly worked for Smith and Nephew Ltd as managing director of subsidiary BSN Medical UK, and joined Almac in 2005 as VP Business Development for Almac Diagnostics. He can be etched at michael.sloan@almacgroup.com
Content From This Contributor:
- New Breast Cancer Chemo Response Test Predicts Benefit from DNA Damage-based Chemotherapy Drugs [Article]
Copyright ? 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
